cyrilzakka/clinical-trials huggingface dataset:
Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic

Doctors are at high risk of corona virus infection (COVID-19) during pandemic. The investigators are aiming to explore the emotions, perceived stressors, knowledge and coping strategies of doctors who are working during COVID-19 pandemic in different specialties and in different hospitals by a self assessment questionnaire that was designed and modified from two previously published articles (mentioned in the references), including 7 sections with 88 questions.

Background

Corona virus disease 2019 (COVID-19), an infectious respiratory disease caused by a newly discovered corona virus in December 2019, has been recognized as a serious threat to global health. Since the WHO declared COVID-19 a pandemic in early March 2020, the WHO and the Center for Disease Control and Prevention (CDC) have been considered the most reliable sources of information for the COVID-19 global pandemic. The CDC listed moderate to severe asthma, especially if not well controlled, as high-risk for severe illness from COVID-19.

A large number of cases occurred among health care workers (HCW), which were contracted within the health care facilities. Some of the HCWs even died from the COVID-19 disease. Moreover, it was reported that unrecognized, asymptomatic patients transferred to their family or close contacts. All these factors were alarming and potentially distressing for the hospital staff who worked during the pandemic.

The severe acute respiratory syndrome (SARS) epidemic in 2003 also involved disease transmission to HCWs. Even though the fatality rates for SARS were lower than for COVID-19 infection, nonetheless, they were a cause of significant stress, emotional turmoil, and concern for all the SARS healthcare providers.

The emotions, perceived stressors, complete knowledge assessment and coping strategies of HCWs especially doctors during COVID-19 have not been explored. These issues were the intended focus of the study.

Eligibility Criteria:
Inclusion Criteria:

* doctors from different specialties

Exclusion Criteria:

* doctors who stopped working in the pandemic
Effects on Health Status in Patients Early Discharged After Primary Percutaneous Coronary Intervention (PCI)

In patients with ST elevation myocardial infarction (STEMI)treated with primary percutaneous coronary intervention (PPCI) a subset with low risk for late complications can be identified. Early discharge (\<72h) of these patients can compromise initiation of prophylaxis, information and other investigations. The researchers want to investigate prospectively whether early discharge compared to regular care have comparable patient centered outcomes at 30 days follow-up.

The safety and feasibility of early discharge of low-risk STEMI treated with thrombolysis or PPCI patients have previously been investigated. It is possible to identify a subset of patients with very low risk for subsequent cardiac events in the short-term, where prolonged hospital stay beyond three days does not alter the outcome. Early discharge have however, not been included in STEMI management guidelines formally. The effects of this discharge regimen on STEMI patients' health status (symptoms, functional capacity and quality of life) is not previously investigated. Shorter hospital stays saves health care resources. On the other hand, short in-hospital stay can affect the perceived satisfaction of care. Initiation of medical treatment, patient education, life style counselling and follow-up routines may suffer. Additionally, early discharge can increase anxiety and symptom level reducing the health related quality of life (HRQOL) and also lead to readmission. Patient satisfaction has become a recognised measure of the quality of health care.Currently there is little information on how early discharge influence the patients' satisfaction with the health care or the subjective perceived of HRQOL after discharge. We therefore wish to perform a prospective trial comparing outcomes with regard to satisfaction of care and HRQOL in patients admitted for STEMI randomised to either early discharge or standard care.

Eligibility Criteria:
Inclusion Criteria:

* ST elevation acute myocardial infarction
* Undergoing primary PCI

Exclusion Criteria:

* Zwolle low risk criteria score \>4
* Re-infarction, post AMI ischemia.
* Need for urgent repeat invasive procedures.
* Non-cardiac complication (bleeding, stroke oa.) or concomitant diseases likely to increase length of hospital stay.
* Patient or caring physician refuse to early discharge or study inclusion.
* Early discharge impossible due to social, nursing or family reasons.
Investigation of High Resolution Nuclear Breast Imaging Camera (MBI) in Patients Administered Tc-99m Sestamibi (ROSE)

This research protocol is designed to evaluate a novel imaging camera, only one of three of it's kind in existence, in the diagnosis of breast cancer. The Molecular Breast Imaging Camera (MBI) is a gamma camera that images accumulation of 99mTc-Sestamibi, a radiopharmaceutical with high affinity for tissues of high cellularity and mitochondrial content; a common characteristic of breast cancers.

This camera represents a significant advancement over its predecessors as it has improved imaging geometry since it can be in direct contact with breast tissue and improved gamma photon detection capability through the use of cadmium zinc telluride (CZT) crystals (a semiconductor material) instead of NaI used in standard gamma cameras.

This project involves imaging patients with a baseline population risk of breast cancer, referred for myocardial perfusion imaging (MPI). This is possible because 99mTc-sestamibi is also used to image myocardial tissue. After the MPI study is performed to standard clinical specifications, the patient is simply imaged with the MBI.

The primary endpoint of this project is to assess acceptability of this imaging device by the patient through the use of a patient survey. Secondary endpoints are to correlate any findings on the MBI studies with standard breast imaging modalities including mammogram, ultrasound, and MRI. Image quality will be evaluated by the interpreting physicians. Also, in an effort to reduce radiation absorbed dose to the female breast, low injected dose images, obtained through post-processing by reframing acquired images, will be assessed for acceptable image quality and diagnostic accuracy.


Eligibility Criteria:
Inclusion Criteria:

* females over 18 years of age
* completed a cardiac stress test using Tc-99m Sestamibi as the radiotracer prior to MBI imaging on the same day.
* signed consent form

Exclusion Criteria:

* pregnant or lactating
* history of invasive breast cancer or ductal carcinoma in situ
* prior bilateral mastectomy
* prior breast biopsy or surgery within 3 months
* any other conditions that based on the investigator's judgement, may impact the ability of the patient to complete the study
A Usability Study of External Neuromodulation With iTEAR100 Generation 2

A Usability Study of External Neuromodulation With iTEAR100 Generation 2. A study which evaluates user ability to train and access the iTEAR100 device in a telehealth environment.

A Usability Study of External Neuromodulation With iTEAR100 Generation 2. A study which evaluates user ability to train and access the iTEAR100 device in a telehealth environment. Subjects sign a consent form and are sent a device. After downloading a mobile app, they can access the device and download a prescription. At 7 days, an official telehealth visit evaluates their success in the set up and training. At 30 days, the trial ends, A usability survey and symptom evaluation survey are used to determine success.

Eligibility Criteria:
Inclusion Criteria: Able to sign English language consent form and over age 18 and reside in the U.S.

-

Exclusion Criteria:

-
Neutral Endopeptidase for Early Detection of Acute Kidney Injury After Cardiac Surgery

The investigators want to investigate if the urinary biomarker neprilysin can identify cardiac surgical patients suffering from postoperative AKI within 24 hours.

Acute kidney injury (AKI) is a common complication following cardiac surgery and significantly increases morbidity, duration of hospital stay, and mortality. The diagnosis of AKI relies on changes in serum creatinine (SCr) from a baseline value or decreases in urine output. Nevertheless changes of SCr to diagnose AKI are only reliable after a minimum of 48 hours.

Neutral endopeptidase, also called neprilysin (NEP) represents a single-pass membrane glycoprotein with zinc-dependent endopeptidase activity and a short cytosolic tail and is found in epithelia, fibroblasts, and neutrophils and in soluble form in the circulation, urine, and cerebrospinal fluid. Beside the focus of interest in cardiovascular medicine for its role in heart failure, where the inhibition of NEP by the administration of sacubitril/valsartan may achieve an improvement in patients with chronic heart failure and reduced ejection fraction, there is also thought to be a link to renal damage.

NEP is expressed in the brush border of proximal tubular cells, which is first shed in renal damage and therefore it is a marker for tubular damage when it is measurable in urine In this study the investigators want to investigate if NEP is a marker for earlier detection of AKI after elective cardiac surgery compared to the currently recommended Kidney Disease - Improved Global Outcomes (KDIGO) guidelines for acute kidney injury. Also, the investigators want to investigate at predefined time points the occurrence and the progression of tubular damage during cardio-pulmonary bypass (CPB) in a closed-meshed NEP detection.

Eligibility Criteria:
Inclusion Criteria:

- Patients undergoing an elective cardiac surgical intervention

Exclusion Criteria:

* Emergency procedures
* Heart transplantation
* Elective left ventricular assist device (LVAD) implantation
* Pulmonary thrombendarterectomy
* Declined informed consent
* Age \< 18 years
* Pregnant woman
* Preoperative renal replacement therapy (RRT)
* Receiving medication containing sacubitril
Evaluate the Safety of Linaclotide in IBS-C Patients in China

This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for half year.

This is a multi-center, one arm, prospective observational study which enrolls approximately 3,000 Chinese patients in China.The study will be performed under real world clinical practice setting. Patients will be eligible for the study after taking at least one dose of linaclotide. Every patient will be followed maximum of 6 months after enrollment. Study measures will be collected at baseline and during the follow-up period. Incidence of adverse events will be employed to assess the safety and tolerability of linaclotide in Chinese patients. The treatment satisfaction will be employed to assess the impact of treatment. The Irritable Bowel Syndrome-Quality of Life Measure (IBS-QoL) will be employed to assess the patient's quality of life.

Eligibility Criteria:
Inclusion Criteria:

* ≧ 18 years old
* Provision of subject informed consent prior to any study procedures
* Has taken at least one dose of linaclotide
* NOT participating in any interventional study currently or during the last 3 months

Exclusion Criteria:

* If linaclotide is contraindicated according to the product prescribing information
* Being unable to comply with study-specified procedure
* Has ever participated in current study before -
Cricothyroidotomy Training for Physicians Outcomes Study

This study will assess whether the type of simulation model used in cricothyroidotomy training has an effect on the subsequent confidence and competence in the procedure.

This is a Pilot study - prospective randomised controlled trial involving:

1. Assessment of ability to complete a surgical cricothyroidotomy
2. Completion of questionnaire prior to training and prior to assessment

Prior to beginning training, questionnaires will be completed by all participants asking their level of previous training. Current confidence level for completion of cricothyroidotomy will be marked on a visual analogue scale (VAS).

Training will then be completed with each group using the appropriate manikin type - porcine or synthetic. This will consist of didactic information on the procedure delivered via recorded information to standardise this initial training, and then proceeding to supervised practice of the procedure for two occasions. This will be completed by the same trainer, with the same information given to both groups. Questions to clarify how to perform the procedure will be permitted.

The second questionnaire will be given to the trainees on completion of training to mark on a visual analogue scale their confidence level at this point.

Assessment will then be completed later the day comprising of assessment of completion of surgical cricothyroidotomy using a porcine manikin with skin overlying. This will be different to the porcine manikin used for training. The assessment will time the trainees from start to completion of airway insertion, as well as a checklist of activities to be achieved. The porcine manikins will then be dissected to identify if correct location for insertion was achieved and complications. The same amount of time will be given between groups training and assessment.

Eligibility Criteria:
Inclusion Criteria:

* Medically trained healthcare professionals working in Anaesthetics, Emergency Medicine or General Surgery as these doctors may be expected to complete a surgical cricothyroidotomy despite infrequently performing the procedure.
* The healthcare professionals can be from Foundation Year 1 to before Certificates of Completion of Training (CCT). Those who are out of training and are not yet at consultant level are also eligible.
* Able to provide informed consent.

Exclusion Criteria:

• Healthcare professionals who already complete surgical airways on a regular basis (e.g. Ear Nose Throat or Maxillofacial trainees) as these doctors may already be competent prior to training.
Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on upper airway collapsibility and genioglossus muscle activity (EMG GG) during sleep in OSA patients.

Two overnight sleep studies, a placebo night and a drug night, will be performed approximately one week apart in random order. The placebo or drug will be administered 2 hours before lights out. At least 15 minutes of quiet wakefulness will be recorded to quantify the participant's EMG GG activity while awake and at sleep onset (alpha-theta transition at the electroencephalogram).

During the second part of the night, the participants will be connected to a modified continuous positive airway pressure (CPAP) machine (Pcrit3000, Respironics) which can provide a wide range of pressures between 20 and -20 cmH2O in order to modify upper airway pressure and measure pharyngeal critical collapsing pressure (Pcrit), ventilation at 0 cmH2O when UA muscle are passive and active as well as change in EMG GG as a function of epiglottic pressure (muscle responsiveness).

Apnea-hypopnea index (AHI) will be calculated in each night from the part of the study off CPAP.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed OSA (moderate-to-severe; apnea hypopnea index \>15 events/hr)

Exclusion Criteria:

* Cardiovascular disease other than well controlled hypertension
* Depression
Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

The purpose of this trial is to compare the safety, tolerability, and efficacy of adding MK-1029 to montelukast in adults with persistent asthma that is uncontrolled while receiving montelukast alone. Participants will have a specific genetic marker for clinical efficacy of MK-1029. The primary hypothesis is that when added to montelukast, treatment with MK-1029 is superior to placebo, as demonstrated by an increase in forced expiratory volume in one second (FEV1), measured as the average change from baseline at the end of Week 4 and Week 6 of treatment.


Eligibility Criteria:
Inclusion Criteria:

* Symptoms of persistent asthma for at least one year
* History of asthma treatments including "as-needed" inhaled short-acting beta-agonists (albuterol/salbutamol); stable doses of inhaled corticosteroids (ICS), combination ICS/long-acting (inhaled) Beta2-adrenergic agonist (LABA) and/or oral asthma controller(s)
* Must be able to discontinue or taper asthma controlling medications while receiving Montelukast
* No history of smoking or no smoking for at least 1 year, with a smoking history of no more than 10 pack-years
* Body Mass Index (BMI) of 15 kg/m\^2 to 40 kg/m\^2.
* Females must not be pregnant (negative serum human chorionic gonadotropin test) or breastfeeding and must not plan to become pregnant for the duration of the study, including the post-treatment follow-up period
* Women and male participants of reproductive potential must agree to use adequate contraception for the duration of the study

Exclusion Criteria:

* Evidence of another active pulmonary disorder such as bronchiectasis or chronic obstructive pulmonary disease (COPD)
* Unable to perform acceptable, repeatable spirometry
* History of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months of screening visit
* Major surgical procedure(s) within 4 weeks of screening visit
* Blood donation within 2 weeks of screening visit
* Treatment in an emergency room for asthma (within 4 weeks) or hospitalization for asthma or respiratory condition within 2 months of screening visit
* Evidence of active sinus disease within 2 weeks of screening visit
* Upper respiratory infection (viral or bacterial) within 1 month of screening visit
* History of a psychiatric disorder within 3 months of screening visit
* History of human immunodeficiency virus (HIV)
* Unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
* History of cancer (except for successfully treated basal and squamous cell carcinomas of the skin) within 5 years of screening visit
* Uncontrolled hypertension
* Participation in a clinical trial involving an investigational drug within 4 weeks of screening visit
* Hypersensitivity or intolerance to inhaled beta-agonists and/or leukotriene inhibitors or any of their ingredients, including lactose and galactose
* Known sensitivity to or has not had previous exposure to aspirin or non-steroidal anti-inflammatory drugs
Analgesic Efficacy of Fascia Iliaca Compartment Block Compared With Intrathecal Nalbuphine for Hip Surgery Under Spinal Anesthesia

It is already known that fascia iliaca compartment block and intrathecal nalbuphine are very effective ways in postoperative pain control in patients having hip surgeries.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) score (ASA I- ASA II).
* Age ≥ 21years.
* Body mass index \< 35 kg/m2

Exclusion Criteria:

* Patient's refusal.
* Known coagulopathy.
* Known peripheral neuropathy or neurological deficits.
* Known allergy to study drugs
Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis

It is a multi-center, double -blind, placebo -controlled, randomized post-marketing study in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo.

Sanjie Analgesic Capsule is a Chinese Traditional Patent Medicine. It is a botanical extract from the raw materials of the Resina Draconis , Panax Notoginseng, fritillary bulb and coix seed, which are derived from a classic prescription of traditional Chinese medicine.

Sanjie Analgesic Capsule was approved by CFDA in 2004, produced by means of modern technology by Jiangsu Kanion Pharmaceutical Co., Ltd. The study is a multi-center, double -blind, placebo-controlled, randomized in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo.

Eligibility Criteria:
Inclusion Criteria:

* Subjects have a diagnosis of endometriosis by laparoscopy within 5 years prior to signing ICF, main complain of dysmenorrhea (or menstrual pain or painful periods) and with VAS score of 4 or above; Endometriosis combined with uterine adenomyosis is included.
* Female between the ages of 18 and 45 years old;
* Regular menstrual period, menstrual cycle falls in the ranging from 28 to 30 days;
* No pregnancy planning during taking study medication; use (or have their partner use) an acceptable method of birth control within the projected duration of the study ;
* Subjects must sign ICF and agree for follow up.

Exclusion Criteria:

* Genital cancer or other malignant tumor;
* Adnexal masses≥5cm;
* Uterine myoma≥3cm;
* Suffering from cardiovascular, hepatic, renal or hematopoietic system disease or mental illness;
* Receiving hormone therapy within 3 months prior to signing ICF;
* Receiving surgical treatment for endometriosis within 3 months prior to signing ICF;
* Subjects have a plan of pregnancy, being pregnant, breast-feeding during recent 3 months.